; (B) describes the specific demonstration programs carried out pursuant to this section; (C) evaluates the effectiveness of such programs; (D) evaluates any unintended consequences of such programs; and (E) provides recommendations for ensuring that medication-assisted treatment is accessible to adolescents and young adults with opioid use disorders. (f) Definitions In this section: (1) The phrase adolescents and young adults means individuals who have attained 10 years of age and not yet attained 26 years of age. (2) The term medication-assisted treatment means the combination of pharmacological treatments approved by the Food and Drug Administration, and counseling and behavioral therapies, for the treatment of substance use disorders. (3) The term opioid use disorder means a problematic pattern of opioid use leading to clinically significant impairment or distress occurring within a 12-month period. (4) The term pediatric health care provider means a provider of health care to individuals who have attained 10 years of age and not yet attained 26 years of age. (5) The term professional family medicine provider organization means a national organization whose members consist primarily of family medicine providers. (6) The term professional pediatric provider organization means a national organization whose members consist primarily of pediatric health care providers. (g) Authorization of appropriations There is authorized to be appropriated $5,000,000 to carry out this section.